Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS-1304 in advanced malignant tumors
NCT06823609Phase 1Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QLS1304 in Advanced Malignant Solid Neoplasm (AMSN), sponsored by Qilu Pharmaceutical. Primary endpoints: Dose Limited Toxicity at 35 days, Maximum Tolerated Dose at 35 days and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
QLS1304
03
Conditions
Advanced Malignant Solid Neoplasm (AMSN)
Beyond the preview
Go deeper on NCT06823609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06823609.